Patients, payers await pricing plans for bluebird's first approved gene therapy
By Elizabeth S. Eaton, Staff Writer | Jun 3, 2019 | 8:40 PM GMT
bluebird gained the first European approval of Zynteglo, a β-thalassemia gene therapy Monday, but payers and patients will have to wait until the end of next week for the company to announce pricing and commercialization plans.
Read the full 371 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD